Enrollment Complete in Tria™ Biopolymer Valve Study

Novel Tria aortic heart valve

The novel TRIA™ surgical aortic heart valve from Foldax®, Inc. has completed enrollment in its U.S. early feasibility study.

Background

Foldax claims its TRIA valve “reimagines the heart valve”. Tria is designed to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. The valve combines the company’s proprietary LifePolymer™ biopolymer with an innovative design.

In a press release, Foldax says TRIA is the first and only heart valve to be robotically produced. This is possible because of the polymer leaflets. As a results these can be consistently manufactured with precise thicknesses. Furthermore the leaflets are designed to deliver predictable performance that lasts a lifetime. 

The early feasibility study of the TRIA surgical aortic heart valve encompassed 40 patients studied at five sites in the U.S. The study was initially approved as a 15-patient study. However upon review of the initial outcomes, the FDA subsequently approved an expansion to add 25 patients.

Investigator comments

Geoff Answini, MD, Chief, Division of Cardiovascular Surgery at The Christ Hospital, Cincinnati, Ohio, and an investigator in the study stated: “We were thrilled to participate in the first human study of the novel TRIA biopolymer heart valve, which offers the potential to improve upon the durability of commonly used tissue valves today.”

“Several of our patients have reached one-year follow-up with good outcomes and we look forward to seeing how a polymer heart valve performs for them over time.”

Company comments

“This first clinical trial of our novel TRIA heart valve technology is a landmark in the heart valve replacement market. It is the first biopolymer valve ever to be studied in man. We have also recently commenced an early feasibility study of our surgical mitral valve and are fast-tracking development of our transcatheter aortic heart valve (TAVR). We have been pleased with the performance of the surgical aortic valve and now have over 30 patient-years of cumulative experience with patients out over two years that are off anticoagulation therapy. We are looking forward to publishing our one-year results and pursuing our IDE with the FDA,” said Frank Maguire, Chief Executive Officer of Foldax.

Source: Foldax, Inc.

Share your thoughts

Your email address will not be published. Required fields are marked *